Norway, Nov. 18 -- Circio Holding ASA, a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, today announces that it has entered an agreement with one of the major global pharmaceutical corporations to conduct a feasibility study of circVec-enhanced gene therapy. The feasibility study involves testing of Circio's circVec circular RNA expression technology for delivery with AAV vectors in a specific therapeutic area. The project will be performed by Circio and is fully funded by the pharmaceutical company. The agreement does not include any downstream rights or obligations on either party.
Published by HT Digital Content Services with permission from Pivotal Sources....